lnu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Functional evaluation of complement factor I variants by immunoassays and SDS-PAGE
Linnaeus University, Faculty of Health and Life Sciences, Department of Chemistry and Biomedical Sciences. (Linnaeus Ctr Biomat Chem, BMC)ORCID iD: 0000-0002-6194-6903
Radboud Univ Nijmegen, Netherlands;Amalia Children’s Hospital, Netherlands.
Linnaeus University, Faculty of Health and Life Sciences, Department of Chemistry and Biomedical Sciences. (Linnaeus Ctr Biomat Chem, BMC)ORCID iD: 0000-0001-7050-3445
Radboud Univ Nijmegen, Netherlands;Amalia Children’s Hospital, Netherlands.
Show others and affiliations
2023 (English)In: Frontiers in Immunology, E-ISSN 1664-3224, Vol. 14, article id 1279612Article in journal (Refereed) Published
Abstract [en]

Factor I (FI) is an essential regulator of the complement system. Together with co-factors, FI degrades C3b, which inhibits further complement activation. Genetic mutations in FI are associated with pathological conditions like age-related macular degeneration and atypical hemolytic uremic syndome. Here, we evaluated eight recombinant FI genetic variants found in patients. We assessed FI's co-factor activity in the presence of two co-factors; Factor H and soluble CR1. Different analytical assays were employed; SDS-PAGE to evaluate the degradation of C3b, ELISA to measure the generation of fluid phase iC3b and the degradation of surface-bound C3b using a novel Luminex bead-based assay. We demonstrate that mutations in the FIMAC and SP domains of FI led to significantly reduced protease activity, whereas the two analyzed mutations in the LDLRA2 domain did not result in any profound changes in FI's function. The different assays employed displayed a strong positive correlation, but differences in the activity of the genetic variants Ile55Phe and Gly261Asp could only be observed by combining different methods and co-factors for evaluating FI activity. In conclusion, our results provide a new perspective regarding available diagnostic tools for assessing the impact of mutations in FI.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2023. Vol. 14, article id 1279612
Keywords [en]
factor I, co-factor activity, functional assay, complement regulation, factor H, complement receptor I
National Category
Immunology in the medical area
Research subject
Biomedical Sciences, Immunology
Identifiers
URN: urn:nbn:se:lnu:diva-125912DOI: 10.3389/fimmu.2023.1279612ISI: 001099563400001PubMedID: 37954579Scopus ID: 2-s2.0-85176611010OAI: oai:DiVA.org:lnu-125912DiVA, id: diva2:1818025
Available from: 2023-12-08 Created: 2023-12-08 Last updated: 2024-10-18Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Gerogianni, AlexandraSjöström, Dick J.Nilsson, Per H.

Search in DiVA

By author/editor
Gerogianni, AlexandraSjöström, Dick J.Nilsson, Per H.
By organisation
Department of Chemistry and Biomedical Sciences
In the same journal
Frontiers in Immunology
Immunology in the medical area

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 27 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf